Progyny, Inc. (PGNY)
Stock Price:
$25.87 USD
-0.07 (-0.27%)
Updated Jul 8, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
2.20B |
| Revenue (ttm) |
263.51M |
| Net Income (ttm) |
n/a |
| Shares Out |
85.17M |
| EPS (ttm) |
-0.99 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 8, 2020 |
| Last Price |
$25.87 |
| Previous Close |
$25.94 |
| Change ($) |
-0.07 |
| Change (%) |
-0.27% |
| Day's Open |
25.74 |
| Day's Range |
25.16 - 26.29 |
| Day's Volume |
835,127 |
| 52-Week Range |
13.29 - 36.50 |
More Stats
| Market Cap |
2.20B |
| Enterprise Value |
2.11B |
| Earnings Date (est) |
Dec 2, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
85.17M |
| Float |
35.16M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.99 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.86M |
| Short Ratio |
2.91 |
| Short % of Float |
24.56% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
8.36 |
| PB Ratio |
18.72 |
| Revenue |
263.51M |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
91.63M |
| Net Cash / Share |
1.08 |
| Gross Margin |
17.27% |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
5.48% |
| ROE |
-10.40% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
5 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$29.67*
(14.69% upside)
Low
26.0
Current: 25.87
High
35.0
Target: 29.67
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 230 | 105 | 48.58 |
| Revenue Growth | 117.92% | 116.94% | - |
| Gross Profit | 45.51 | 19.43 | 7.40 |
| Operating Income | 9.68 | -3.45 | -11.01 |
| Net Income | -8.57 | 0.66 | -12.45 |
| Shares Outstanding | 20.74 | 5.54 | 5.68 |
| Earnings Per Share | -0.41 | 0.04 | -2.37 |
| Operating Cash Flow | -1.53 | 2.27 | -9.47 |
| Capital Expenditures | -2.96 | -0.58 | -0.61 |
| Free Cash Flow | -4.49 | 1.69 | -10.09 |
| Cash & Equivalents | 80.38 | 0.13 | 4.69 |
| Total Debt | - | 0.25 | 5.19 |
| Net Cash / Debt | 80.38 | -0.13 | -0.50 |
| Assets | 150 | 41.32 | 34.96 |
| Liabilities | 36.16 | 30.20 | 24.27 |
| Book Value | 114 | -95.12 | -97.62 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Progyny, Inc. |
| Country |
United States |
| Employees |
167 |
| CEO |
David J. Schlanger |
Stock Information
| Ticker Symbol |
PGNY |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Health Information Services |
| Unique Identifier |
NASDAQ: PGNY |
Description
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption expenses for clients and their employees. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.